Ann: NTI to Present at Rett Syndrome Foundation Meeting, page-6

AgentQ/mj873: You are both correct, i.e. Neuren's product is indeed quite/very expensive. However, it has now "first mover advantage" and IF it is very helpful and effective in combating RETT SYNDROM (which the FDA approval that it received implies resp. confirms), then NTI's product will have to also get FDA approval and moreover then try to dislodge the persons that are now starting to use Neuren's (resp. Acadia's) RETT syndrome fighter... NOT a simple task! And how (very) long will it take for NTI to get an FDA approval (on its own or with a partner perhaps...)?

wasa

PS: In my view, it would still be wiser for NTI to concentrate on other projects than fighting RETT Syndrome. There are more than enough 'rare diseases' that need effective solutions. Sorry for my musings as a non-holder!